An Open-Label, Non-randomized, Multi-center Phase I Study Evaluating the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Bi-Ligand-Drug Conjugate CBP-1018 in Patients With Advanced Solid Tumors
Latest Information Update: 09 Jul 2024
At a glance
- Drugs CBP-1018 (Primary)
- Indications Bladder cancer; Carcinoma; Lung cancer; Prostate cancer; Renal cell carcinoma; Solid tumours; Squamous cell cancer; Ureteral neoplasms
- Focus Adverse reactions; First in man; Therapeutic Use
- Sponsors Coherent Biopharma (Suzhou)
- 04 Jun 2024 Results presented at the 60th Annual Meeting of the American Society of Clinical Oncology
- 24 Oct 2023 Results (n=20; As of 27 April 2023) assessing the safety, preliminary efficacy and pharmacokinetics of CBP-1018 in patients with advanced solid tumors, presented at the 48th European Society for Medical Oncology Congress.
- 06 Jun 2023 Results (n=14) presented at the 59th Annual Meeting of the American Society of Clinical Oncology